Barinthus Biotherapeutics (BRNS) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free BRNS Stock Alerts $2.50 +0.07 (+2.88%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by HC Wainwrightamericanbankingnews.com - April 21 at 1:36 AMBarinthus Biotherapeutics (NASDAQ:BRNS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 19 at 3:27 PMInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectivesmarkets.businessinsider.com - April 19 at 1:12 PMBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infectionsglobenewswire.com - April 18 at 4:10 PMShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 15.1%marketbeat.com - April 14 at 5:32 PMBRNS Barinthus Biotherapeutics plcseekingalpha.com - April 14 at 10:53 AMBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023finance.yahoo.com - March 22 at 5:53 PMWilliam Blair Comments on Barinthus Biotherapeutics plc's Q1 2025 Earnings (NASDAQ:BRNS)marketbeat.com - March 22 at 8:35 AMBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $8.00 Price Target at HC Wainwrightmarketbeat.com - March 21 at 12:40 PMBarinthus Biotherapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 12:14 PMBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developmentsglobenewswire.com - March 20 at 8:15 AMIndividual investors account for 48% of Barinthus Biotherapeutics plc's (NASDAQ:BRNS) ownership, while institutions account for 25%finance.yahoo.com - March 4 at 10:58 AMBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Updatemarketbeat.com - February 29 at 7:44 AMBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Dividends: History, Yield and Datesbenzinga.com - February 25 at 10:37 AMBarinthus Biotherapeutics (NASDAQ:BRNS) Shares Up 3.1%marketbeat.com - February 23 at 3:50 AMBarinthus Biotherapeutics plc to Post FY2023 Earnings of ($2.03) Per Share, HC Wainwright Forecasts (NASDAQ:BRNS)marketbeat.com - January 10 at 7:26 AMBarinthus Biotherapeutics (NASDAQ:BRNS) Earns "Outperform" Rating from William Blairmarketbeat.com - January 8 at 8:16 AMmarketbeat.com - November 7 at 10:20 AM Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy BRNS Media Mentions By Week BRNS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRNS News Sentiment▼-0.080.32▲Average Medical News Sentiment BRNS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRNS Articles This Week▼20▲BRNS Articles Average Week Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLSD News Today ANIX News Today VACC News Today IOBT News Today ORMP News Today DMAC News Today BTAI News Today CLRB News Today PRPH News Today GNLX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BRNS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
